Onco Actu du 29 novembre 2019

	1.1 BIOLOGIE - GÉNOME
From Genes to Cancer and Back - Siddhartha Mukherjee [NHGRI] The 2019 NHGRI Symposium provides an exciting forum for the exchange of scientific and research ideas, forging of new collaborations, and networking across the Institute. The symposium featured a keynote presentation from Dr. Siddhartha Mukherjee, noted biologist, oncologist, and author of The Gene: An Intimate History. [video : 1h 10mn]
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Home urine test for prostate cancer could revolutionize diagnosis [EurekAlert!] Their latest study shows how the 'PUR' test (Prostate Urine Risk) could be performed on samples collected at home, so men don't have to come into the clinic to provide a urine sample - or have to undergo an uncomfortable rectal examination.
	4.5 DÉP., DIAG. & PRONO. - COLORECTAL
Poo tests: looking for cancer clues in poo [Cancer Research UK] Probert and his team are taking a different approach. They’re investigating if chemicals that come from the gut can help doctors detect the early signs of cancer, in a project called VODECA (Volatile Organic compounds for the DEtection of Colorectal cAncer).
	5. TRAITEMENTS
New path forward for pancreatic cancer treatment [Garvan Institute] Dr Omid Faridani, recipient of the 2019 Pathfinders Award, is developing a new device that can isolate these spreading cancer cells from a patient’s blood, and look for signatures that could indicate how effective cancer treatment is.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Use combined chemical probe resources to select best tools for biomedical research and drug discovery, scientists urge [Institute of Cancer Research] The report strongly recommends that researchers should avoid general search engines and vendor catalogue information and instead use two kinds of online resource – expert reviews and computational Big Data approaches – in order to make the best decisions about which chemical probes to use in biomedical research, and also to avoid poor selection of tools that can lead to incorrect conclusions.
	5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
OSE Immunotherapeutics And HalioDx Collaborate To Perform Immune Biomarker Exploratory Work During Atalante 1 Phase 3 Clinical Trial Of Tedopi® In Non-small Cell Lung Cancer [HalioDx] The collaboration will focus on the testing and analysis of clinical biopsy tissue samples from patients participating in the ongoing Phase 3 Atalante 1 clinical trial. HalioDx will leverage its expertise in proprietary technology immuno-oncology diagnostic platforms to perform immune biomarker exploratory work as part of the clinical trial objectives.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Novartis opens facility for innovative cell and gene therapies in Switzerland [Novartis] In addition to manufacturing areas for novel CAR-T cell therapies, the new building also hosts the production of innovative, difficult-to-manufacture solid dosage forms such as tablets and capsules.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer [AstraZeneca] The sBLA was based on positive results from the Phase III CASPIAN trial published in The Lancet, showing Imfinzi in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) vs. SoC.
AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer [Reuters] The FDA decision is a boost for the treatment as it competes against similar medicines from rivals Merck and Roche, and follows data in September which showed Imfinzi prolonged survival in SCLC patients when used with chemotherapy.
	5.2.3 PHARMA - ÉCONOMIE
Drugmakers cut prices by 61% to get on Chinese reimbursement list [Pharmafile] The National Healthcare Security Administration said on its website that seventy new drugs are being added to China’s state-run medical insurance fund. This includes Novartis’s dermatitis treatment Xolair (omalizumab), Roche’s breast cancer treatment Perjeta (pertuzumab), and AbbVie’s arthritis treatment Humira (adalimumab).
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
EMA Recommends Granting a Conditional Marketing Authorisation for Polatuzumab Vedotin [ESMO] It is intended for the treatment of relapsed/refractory DLBCL in combination with bendamustine and rituximab.
	5.4 TRAITEMENTS - ECONOMIE
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy [Institute of Cancer Research] Women with oestrogen receptor-positive breast cancer whose disease has already spread, and who have received hormone therapy, will now be eligible for palbociclib on the NHS through the Cancer Drugs Fund.
	6. LUTTE CONTRE LES CANCERS
Rwanda leads fight against cervical cancer in Africa [BBC News] Cervical cancer is the fourth most common cancer among women worldwide. But in Africa it is far deadlier than elsewhere, despite being a preventable disease. An ambitious health campaign in Rwanda has set an example which other countries on the continent are now starting to follow.
	6.11 PATIENTS
Clive James raised awareness of leukaemia, part of his rich and valuable legacy [The Conversation] Clive James entertained and informed us as he shared his observations on his life through decades of writing. So it is fitting he should be publicly sharing the health issues that resulted in his death. As such, he provided one last opportunity to educate his readers — in this instance about leukaemia.
	6.7.3 DMP
Google Health unveils EHR data aggregation tool for clinicians [Digital Health] Rather than a fully-fledged EPR system – which Google representatives have previously suggested the company is not interested in – the demo hints towards an interoperable platform that sits on top of the clinical desktop.